EW Roberts, A Deonarine, JO Jones, AE Denton, C Feig, SK Lyons, M Espeli, M Kraman, B McKenna, RJB Wells, Q Zhao, OL Caballero, R Larder, AP Coll, S O'Rahilly, KM Brindle, SA Teichmann, DA Tuveson, DT Fearon
Journal name: 
J Exp Med
Citation info: 
Fibroblast activation protein-α (FAP) identifies stromal cells of mesenchymal origin in human cancers and chronic inflammatory lesions. In mouse models of cancer, they have been shown to be immune suppressive, but studies of their occurrence and function in normal tissues have been limited. With a transgenic mouse line permitting the bioluminescent imaging of FAP(+) cells, we find that they reside in most tissues of the adult mouse. FAP(+) cells from three sites, skeletal muscle, adipose tissue, and pancreas, have highly similar transcriptomes, suggesting a shared lineage. FAP(+) cells of skeletal muscle are the major local source of follistatin, and in bone marrow they express Cxcl12 and KitL. Experimental ablation of these cells causes loss of muscle mass and a reduction of B-lymphopoiesis and erythropoiesis, revealing their essential functions in maintaining normal muscle mass and hematopoiesis, respectively. Remarkably, these cells are altered at these sites in transplantable and spontaneous mouse models of cancer-induced cachexia and anemia. Thus, the FAP(+) stromal cell may have roles in two adverse consequences of cancer: their acquisition by tumors may cause failure of immunosurveillance, and their alteration in normal tissues contributes to the paraneoplastic syndromes of cachexia and anemia.
Research group: 
Brindle Group
E-pub date: 
03 Jun 2013
Users with this publication listed: 
Christine Feig
Doug Fearon
Kevin Brindle